Imatinib resistance in gastrointestinal stromal tumors

Current Oncology Reports

Volumn 7, Issue 4, 2005, Pages 293-299

  Chen, Lei L ^a   Sabripour, Mahyar ^a   Andtbacka, Robert H I ^a   Patel, Shreyaskumar R ^a   Feig, Barry W ^a   Macapinlac, Homer A ^a   Choi, Haesun ^a   Wu, Elsie F ^a   Frazier, Marsha L ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALANINE; ASPARTIC ACID; BCR ABL PROTEIN; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; IMATINIB; ISOLEUCINE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; THREONINE; TYROSINE; UNCLASSIFIED DRUG; VALINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYSTALLOGRAPHY; DOSE RESPONSE; DRUG PROTEIN BINDING; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INHIBITION KINETICS; LIVER METASTASIS; LUNG METASTASIS; META ANALYSIS; MISSENSE MUTATION; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROTEIN DOMAIN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; DRUG RESISTANCE; GENETICS; PATHOLOGY; RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION, MISSENSE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 23444437980     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0053-6     Document Type: Review

References (32)

1. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
2. Koh JS, Trent J, Chen L, et al.: Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 2004, 19:565-574.
3. Antonescu, CR, Sommer G, Sarran L, et al.: Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: IUT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003, 9:3329-3337.
4. Taniguchi M, Nishida T, Hirota S, et al.: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59:4297-4300.
5. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: gastrointestinal stromal tumors. Cancer Genet Cytogenet 2002, 135:1-22.
6. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
7. Heinrich MC, Corless CL, Deunsing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
8. Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660-667.
9. Manley PW, Cowan-Jacob SW, Buchdunger E, et al.: Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002, 38:S19-S27.
10. van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
11. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
12. Kitamura Y, Hirota S, Nishida T: Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 2003, 94:315-320.
13. Mol CD, Dougan DR, Schneider TR, et al.: Structural basis for the autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J Biol Chem 2004, 279:31655-31663.
14. Debiec-Rychter M, Dumez H, Judson I, et al.: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695.
15. Heinrich MC, Shoemaker JS, Corless CL, et al.: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]. Proc ASCO 2005, 24:7.
16. Blackstein ME, Rankin C, Fletcher C, et al.: Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial [abstract]. Proc ASCO 2005, 24:9010.
17. Chen LL, Trent JC, Wu EF, et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64:5913-5919.
18. Tamborini E, Bonadiman L, Greco A, et al.: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004, 127:294-299.
19. Wakai T, Kanda T, Hirota S, et al.: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004, 90:2059-2061.
20. Nardi V, Azam M, Daley GQ: Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004, 11:35-43.
21. Tauchi T, Ohyashiki K: Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004, 28(Suppl 1):S39-S45.
22. Tosoni A, Nicolardi L, Brandes AA: Current clinical management of gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2004, 4:595-605.
23. Choi H, Chamsangavej C, Faria S, et al.: Correlation of computed tomography (CT) and positron emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate: time to re-visit tumor response criteria. J Clin Oncol, in press.
24. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-Pdb-Viewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
25. Andtbacka RHI, Ng CS, Cormier JN, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Presented at the meeting of the Society of Surgical Oncology, Atlanta, GA, March 3-6, 2005.
26. Antoch G, Kanja J, Bauer S, et al.: Comparison of PET, CT and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45:357-365.
27. Rankin C, Von Mehren M, Blanke C, et al.: Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033. J Clin Oncol 2004, 22:9005.
28. Zalcberg JR, Verweij J, Casali PG, et al.: Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD): an international, Intergroup study of the EORTC, ISG and AGITG [abstract. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22:9004.
29. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
30. Mudan SS, Conlon KC, Woodruff JM, et al.: Salvage surgery for patients with recurrent gastrointestinal sarcoma. Cancer 2000, 88:66-74.
31. Demetri GD, Desai J, Fletcher JA, et al.: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004, 22:3001.
32. Maki, RG, Fletcher JA, Heinrich MC, et al.: Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) [abstract]. Proc ASCO 2005, 24: 9011.